{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:49:57Z","timestamp":1777438197864,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.mvr.2011.04.006","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T04:56:55Z","timestamp":1303707415000},"page":"1-5","source":"Crossref","is-referenced-by-count":19,"title":["Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy"],"prefix":"10.1016","volume":"82","author":[{"given":"Natalia","family":"Marek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Raczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Zorena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"My\u015bliwska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Reiwer-Gostomska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Trzonkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mvr.2011.04.006_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2011.04.006_bb0010","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"suppl. 1","key":"10.1016\/j.mvr.2011.04.006_bb0020","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.2337\/diacare.28.suppl_1.S37","article-title":"Diagnosis and classification of diabetes mellitus","volume":"28","author":"American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mvr.2011.04.006_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/157339910793360842","article-title":"Intravitreal Bevacizumab (Avastin(\u00ae)) for Diabetic Retinopathy at 24-months: the 2008 Juan Verdaguer-Planas Lecture","volume":"6","author":"Arevalo","year":"2010","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.mvr.2011.04.006_bb0030","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2011.04.006_bb0035","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1073\/pnas.86.5.1573","article-title":"Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2","volume":"86","author":"Bicknell","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mvr.2011.04.006_bb0040","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/sj.eye.6702138","article-title":"Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy","volume":"20","author":"Demircan","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.mvr.2011.04.006_bb0045","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3109\/02713689508998529","article-title":"Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy","volume":"14","author":"Elner","year":"1995","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.mvr.2011.04.006_bb0050","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","article-title":"Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularisation using a modified \u201ctreat and extend\u201d dosing regimen of intravitreal antivascular endothelial growth factor therapy","volume":"30","author":"Engelbert","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.mvr.2011.04.006_bb0055","doi-asserted-by":"crossref","unstructured":"Ergul, A., in press. Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacol. Res. doi:10.1016\/j.phrs.2011.01.012.","DOI":"10.1016\/j.phrs.2011.01.012"},{"key":"10.1016\/j.mvr.2011.04.006_bb0060","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","article-title":"Diabetic retinopathy","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mvr.2011.04.006_bb0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ajo.2007.07.022","article-title":"Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth. factor and hypoxia-inducible factor-1alpha","volume":"144","author":"Forooghian","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0070","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/112067211002000604","article-title":"Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy","volume":"20","author":"Hern\u00e1ndez-Da Mota","year":"2010","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0075","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":"Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.mvr.2011.04.006_bb0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9440(10)64869-9","article-title":"Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo","volume":"160","author":"Joussen","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1096\/fj.02-0157fje","article-title":"Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood\u2013retinal barrier breakdown in a model of streptozotocin-induced diabetes","volume":"17","author":"Joussen","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.mvr.2011.04.006_bb0095","doi-asserted-by":"crossref","first-page":"95103","DOI":"10.1155\/2007\/95103","article-title":"Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy","volume":"2007","author":"Kern","year":"2007","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/j.mvr.2011.04.006_bb0100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2169\/internalmedicine.49.2929","article-title":"Synchronized changes in serum vascular endothelial growth factor during the clinical course of chronic systemic capillary leak syndrome","volume":"49","author":"Kinoshita","year":"2010","journal-title":"Intern. Med."},{"key":"10.1016\/j.mvr.2011.04.006_bb0105","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1755-3768.2009.01612.x","article-title":"Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome","volume":"88","author":"Kofoed","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0110","first-page":"40","article-title":"Biological functions and therapeutic properties of angiogenins","volume":"73","author":"Komolova","year":"2010","journal-title":"Eksp. Klin. Farmakol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0115","first-page":"1586","article-title":"Soluble TNF receptors in vitreoretinal proliferative disease","volume":"42","author":"Limb","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mvr.2011.04.006_bb0120","first-page":"1143","article-title":"Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous","volume":"12","author":"Maier","year":"2006","journal-title":"Mol. Vis."},{"key":"10.1016\/j.mvr.2011.04.006_bb0125","first-page":"438","article-title":"Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201\u2013995","volume":"18","author":"Mallet","year":"1992","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.mvr.2011.04.006_bb0130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1573399052952596","article-title":"Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy","volume":"1","author":"Mitamura","year":"2005","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.mvr.2011.04.006_bb0140","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.4049\/jimmunol.172.7.4618","article-title":"Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization","volume":"172","author":"Mor","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0145","doi-asserted-by":"crossref","first-page":"e11103","DOI":"10.1371\/journal.pone.0011103","article-title":"HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia","volume":"5","author":"Mowat","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.mvr.2011.04.006_bb0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2007.07.011","article-title":"The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy","volume":"79","author":"My\u015bliwiec","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.mvr.2011.04.006_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1196\/annals.1348.062","article-title":"Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases","volume":"1082","author":"Ng","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mvr.2011.04.006_bb0160","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2009.03.017","article-title":"Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration","volume":"116","author":"Papadopoulou","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2011.04.006_bb0165","first-page":"1382","article-title":"Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy","volume":"14","author":"Petrovic","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.mvr.2011.04.006_bb0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2174\/157339910793360815","article-title":"Angiogenic growth factors and their inhibitors in diabetic retinopathy","volume":"6","author":"Praidou","year":"2010","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.mvr.2011.04.006_bb0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0065-2423(10)50006-4","article-title":"Ocular angiogenesis: mechanisms and recent advances in therapy","volume":"50","author":"Rajappa","year":"2010","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.mvr.2011.04.006_bb0180","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1167\/iovs.08-2736","article-title":"Tyrosine phosphorylation of vitreous inflammatory and angiogenic peptides and proteins in diabetic retinopathy","volume":"50","author":"Reverter","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mvr.2011.04.006_bb0185","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/bjo.2009.160986","article-title":"Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease","volume":"94","author":"Shimura","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0190","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.2337\/dc07-0629","article-title":"Low serum angiogenin level concentrations in patients with type 2 diabetes","volume":"12","author":"Siebert","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mvr.2011.04.006_bb0195","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2337\/dc10-0130","article-title":"Glycemic control influences serum angiogenin concentrations in patients with type 2 diabetes","volume":"33","author":"Siebert","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mvr.2011.04.006_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.diabres.2005.05.017","article-title":"Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case\u2013control study","volume":"71","author":"Simo","year":"2006","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.mvr.2011.04.006_bb0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000098504","article-title":"Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy","volume":"39","author":"Starita","year":"2007","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/hmg\/ddm290","article-title":"Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension\/pathfinding and survival of motor neurons","volume":"17","author":"Subramanian","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mvr.2011.04.006_bb0215","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1021\/bi902122w","article-title":"Angiogenin induces nitric oxide synthesis in endothelial cells through PI-3 and Akt kinases","volume":"49","author":"Trouillon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.mvr.2011.04.006_bb0220","doi-asserted-by":"crossref","first-page":"30274","DOI":"10.1016\/S0021-9258(18)43808-2","article-title":"Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment","volume":"269","author":"Tschesche","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mvr.2011.04.006_bb0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ajo.2009.07.007","article-title":"Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy","volume":"148","author":"Wang","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0230","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ajo.2004.10.004","article-title":"Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy","volume":"139","author":"Watanabe","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.04.006_bb0235","first-page":"2524","article-title":"Evidence supporting a role for N-(3-formyl-3,4-dehydropiperidino)lysine accumulation in M\u00fcller glia dysfunction and death in diabetic retinopathy","volume":"16","author":"Yong","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.mvr.2011.04.006_bb0240","first-page":"1097","article-title":"Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization","volume":"39","author":"Yoshida","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mvr.2011.04.006_bb0245","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1096\/fj.09-145664","article-title":"Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization","volume":"24","author":"Yoshida","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.mvr.2011.04.006_bb0250","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1056-8727(01)00155-6","article-title":"Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy","volume":"15","author":"Yuuki","year":"2001","journal-title":"J. Diabetes Complications"}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286211000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286211000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T05:34:21Z","timestamp":1637559261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286211000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0026286211000689"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2011.04.006","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}